Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.38 |
| ▸ | PNMT | P11086 | 2/20 | 0.33 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 3/20 | 0.32 |
| ▸ | HTR2B | P41595 | 3/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21500484 | 1.00 | HTR2C (0.38) | HTR2CPNMTASIC3HTR2AHTR2B | |
| SCHEMBL21525908 | 0.78 | KIF11 (0.42) | HTR2CPNMTHTR2AHTR2BKIF11 | |
| SCHEMBL11442883 | 0.78 | HTR2C (0.40) | HTR2CPNMTASIC3HTR2AHTR2B | |
| SCHEMBL29750085 | 0.78 | KIF11 (0.42) | HTR2CPNMTHTR2AHTR2BKIF11 | |
| SCHEMBL11443157 | 0.75 | PNMT (0.44) | HTR2CPNMTASIC3HTR2AHTR2B | |
| SCHEMBL19358009 | 0.75 | CD44 (0.40) | HTR2CPNMTASIC3HTR2AHTR2B | |
| SCHEMBL19406884 | 0.75 | HTR2C (0.38) | HTR2CHTR2AHTR2BKIF11 | |
| SCHEMBL11198207 | 0.71 | HTR2C (0.38) | HTR2CKIF11 | |
| SCHEMBL31498400 | 0.70 | PNMT (0.34) | PNMTASIC3 | |
| SCHEMBL30778182 | 0.70 | CES1 (0.41) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720038-A1 | (HETERO)ARYL-CARBONYL-HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PMS2 FOR CANCER AND DEGENERATIVE ILLNESSES | Neophore Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024246496-A1 | (HETERO)ARYL-CARBONYL-HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PMS2 FOR CANCER AND DEGENERATIVE ILLNESSES | Neophore Limited (GB) | 2024-12-05 | — | — | WO | disclosed |